Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Wonbiogen Co., Ltd. (307280:KRX), powered by AI.
Wonbiogen Co., Ltd. is currently trading at ₩6,260. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Wonbiogen Co., Ltd. on Alpha Lenz.
Wonbiogen Co., Ltd.'s P/E ratio is 6.7.
“Wonbiogen Co., Ltd. trades at a P/E of 6.7 (undervalued) with strong ROE of 16.6%. Operating margin of 23.2% indicates strong profitability.”
Ask for details →Wonbiogen Co., Ltd. is a biotechnology company that focuses on the research, development, and commercialization of innovative biopharmaceutical products. Primarily engaged in creating therapeutic solutions, the company targets major disease areas, including oncology and metabolic disorders, aiming to address unmet medical needs. Renowned for its investment in cutting-edge technology, Wonbiogen integrates advanced research methodologies to enhance its drug discovery and development processes. The company's products, which often stem from its pipeline of new molecule entities, are instrumental in advancing medical innovation within the healthcare sector. By continually expanding its research and strategic partnerships, Wonbiogen plays a significant role in the biopharmaceutical landscape, influencing both domestic and international markets with its robust portfolio of therapeutic solutions. With a commitment to improving patient health outcomes, the company underscores its market significance through ongoing contributions to scientific advancement and healthcare delivery.
“Wonbiogen Co., Ltd. trades at a P/E of 6.7 (undervalued) with strong ROE of 16.6%. Operating margin of 23.2% indicates strong profitability.”
Ask for details →Wonbiogen Co., Ltd. (ticker: 307280) is a company listed on KRX in the Healthcare sector (Medical Instruments & Supplies). It has approximately 76 employees. Market cap is $44.4B.
The current price is ₩6,260 with a P/E ratio of 6.71x and P/B of 1.04x.
ROE is 16.55% and operating margin is 23.24%. Annual revenue is $35.2B.